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ABSTRACT
Objective: To present outcomes in a cohort of medically intractable chronic cluster headache
(CCH) patients treated with ventral tegmental area (VTA) deep brain stimulation (DBS).
Methods: In an uncontrolled open-label prospective study, 21 patients (17 male; mean age 52
years) with medically refractory CCH were selected for ipsilateral VTA-DBS by a specialist mul-
tidisciplinary team including a headache neurologist and functional neurosurgeon. Patients had
also failed or were denied access to occipital nerve stimulation within the UK National Health Ser-
vice. The primary endpoint was improvement in the headache frequency. Secondary outcomes
included other headache scores (severity, duration, headache load), medication use, disability
and affective scores, quality of life (QoL) measures, and adverse events.
Results:Median follow-up was 18 months (range 4–60months). At the final follow-up point, there
was 60% improvement in headache frequency (p 5 0.007) and 30% improvement in headache
severity (p 5 0.001). The headache load (a composite score encompassing frequency, severity,
and duration of attacks) improved by 68% (p 5 0.002). Total monthly triptan intake of the group
dropped by 57% posttreatment. Significant improvement was observed in a number of QoL,
disability, and mood scales. Side effects included diplopia, which resolved in 2 patients following
stimulation adjustment, and persisted in 1 patient with a history of ipsilateral trochlear nerve
palsy. There were no other serious adverse events.
Conclusions: This study supports that VTA-DBS may be a safe and effective therapy for refrac-
tory CCH patients who failed conventional treatments.
Classification of evidence: This study provides Class IV evidence that VTA-DBS decreases head-
ache frequency, severity, and headache load in patients with medically intractable chronic cluster
headaches. Neurology® 2016;86:1676–1682
GLOSSARY
CCH 5 chronic cluster headache; CESG 5 Clinical Effectiveness Supervisory Committee; CH 5 cluster headache; DBS 5
deep brain stimulation; HAL 5 headache load; HIT-6 5 Headache Impact Test–6; IPG 5 implantable pulse generator;
MIDAS 5 Migraine Disability Assessment Scale; NHS 5 National Health Service; ONS 5 occipital nerve stimulation;
PCS 5 physical component summary; QoL 5 quality of life; SF-36 5 Short Form-36; TAC 5 trigeminal autonomic cepha-
lalgia; VRS 5 verbal rating scale; VTA 5 ventral tegmental area.
Cluster headache (CH) is a trigeminal autonomic cephalalgia (TAC)1 characterized by attacks of
severe, strictly unilateral cranial pain associated with ipsilateral cranial autonomic features.2,3 CH has
a prevalence of 0.1%–0.2% and chronic CH (CCH) occurs in 10%–15% of patients whose attacks
occur for more than 1 year without remission, or with remissions lasting less than 1 month.4–8
Standard medical therapy comprises acute and prophylactic treatments, which are usually
effective.9 However, in a small but significant number of highly disabled individuals, attacks
are intractable. For these patients, peripheral (occipital nerve stimulation [ONS] or sphenopal-
atine ganglion stimulation) and central neuromodulation (ventral tegmental area [VTA] deep
brain stimulation [DBS]) have been carried out with promising results.10–15
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We investigated the efficacy of VTA-DBS
when used as a humanitarian intervention in
patients who had exhausted every other option
available to them within the framework of the
UK National Health Service (NHS). We pre-
sent a prospective study of 21 consecutive pa-
tients with CCH, treated using a MRI-guided
and MRI-verified approach to VTA-DBS,
focusing on changes in headache characteristics,
quality of life (QoL), disability, and mood.
METHODS Standard protocol approvals, registrations,
and patient consents. The UK National Institute for Health
and Care Excellence published guidance concerning DBS for
intractable TACs in March 2011 (https://www.nice.org.uk/
guidance/ipg381/chapter/1-Guidance), advising arrangements
for clinical governance, consent, audit, and research. In keeping
with this, and under the supervision of our institution’s Clinical
Effectiveness Supervisory Committee (CESG), we offered VTA-
DBS to CCH patients who had failed ONS or in whom NHS
funding for ONS had been declined. The procedure was provided
on the basis of a humanitarian intervention. Patients were
provided with CESG-approved patient information booklets
and gave written consent.
Patient selection. Included patients fulfilled the International
Classification of Headache Disorders–II diagnostic criteria for
CCH1 and had experienced highly disabling, medically refractory
symptoms for at least 2 years. CCH was classified as medically
intractable if patients failed adequate trials of at least 5 of the
following 7 drugs: verapamil, lithium, methysergide, topiramate,
melatonin, gabapentin, and valproate. A failed trial was defined as
an unsatisfactory response, side effects intolerance, or contraindi-
cation to the agent’s use.16 All patients were considered for ONS
prior to DBS and had either been refused funding or had failed to
respond adequately. Sphenopalatine ganglion stimulation was not
available in the United Kingdom during the study period. Refer-
rals were made by a single tertiary specialist headache clinic to a
DBS multidisciplinary team at the same center. Neuropsycholog-
ical evaluations and MRI brain scans were performed to rule out
cognitive impairment, brain lesions, or significant brain atrophy.
Outcome measures and follow-up. Outcome data were
collected and recorded prospectively and included headache
frequency, headache severity, headache load, disability scores,
affective scores, QoL measures, adverse events (including
surgical complications, stimulation-induced adverse events, and
morbidity), and reduction in preventive and acute treatment.
Headache severity was measured on the verbal rating scale
(VRS) for pain (0 being no pain and 10 being the worst pain
imaginable). Patients reported the mean headache intensity dur-
ing individual attacks. The individual scores were then averaged
over the observation period. Headache frequency was defined as
the number of CH attacks per day. Headache load (HAL) was
defined as
P
(severity [on the verbal rating scale] 3 duration
[in hours]) of all headache attacks occurring over a 2-week period.
These measures were assessed using headache diaries collected
preoperatively (baseline), at commencement of DBS therapy,
and at 3, 6, and 12 months and yearly thereafter. Patients with
multiple headache types kept separate diaries for CH attacks and
other headache syndromes; headache parameters were calculated
for each headache type.
Responders were defined as patients with sustained HAL
reduction $30% since this was deemed meaningful in line with
the Initiative on Methods, Measurement, and Pain Assessment in
Clinical Trials (IMMPACT) guidelines.17
Disability measures, QoL, and affective scores were collected
using questionnaires. The Short Form-36 (SF-36) measuring
both the physical component summary (PCS) and mental com-
ponent summary scores was used to assess health-related QoL
at baseline and after stable improvements in responders, or after
a year of continuous stimulation in nonresponders.18 Since spe-
cific tools for measuring the disability of CH have not yet been
validated, disability was assessed using the Migraine Disability
Assessment Scale (MIDAS)19 and the Headache Impact Test–6
(HIT-6).20 MIDAS and HIT-6 have been used extensively to
assess primary headache disorders. They have previously been
used to assess the disability of CH and hemicrania continua
patients treated with ONS.21,22 The Hospital Anxiety and
Depression Scale–anxiety and Hospital Anxiety and Depression
Scale–depression23 were used to evaluate the presence and degree
of anxiety and depression before and after surgery. Other ques-
tionnaires included the Beck Depression Inventory II and the
EuroQol (EQ-5D).
Surgical procedure. DBS leads were implanted using a stereo-
tactic MRI-guided and MRI-verified approach without
microelectrode recording as detailed in previous publications
(Leksell frame model G; Elekta Instrument AB, Stockholm,
Sweden).24,25 The first 11 patients had lead implantation
performed under local anesthesia; in the remaining 10 patients,
leads were implanted under general anaesthesia.24 The anatomical
target was the ipsilateral VTA. The location for the deepest
contact of the 3389 Medtronic lead was defined on a 1.5T T2-
weighted axial stereotactic MRI at a level immediately above the
mammillary bodies, anteromedial to the hypointense red nucleus
and posterolateral to the hypointense mammillothalamic tract.
Immediately after lead implant, location was verified with a
stereotactic MRI scan (figure 1) in patients without ONS.
Postoperative stereotactic CT scan was performed in patients
with implanted ONS hardware. The lead was then connected
to a single or dual channel implantable pulse generator (IPG)
(Medtronic, Minneapolis, MN) implanted in the infraclavicular
region on the same day of lead implantation or within a week, as a
staged procedure under general anesthesia.
DBS programming. In the weeks following surgery, open label
programming was conducted to define optimal stimulation pa-
rameters. Six patients (29%) had a delay of 1–3 months before
Figure 1 Immediate postoperative stereotactic MRI demonstrates the deep
brain stimulation lead in the left ventral tegmental area
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their stimulation was started. This was because they reported a
clear stun effect period postoperatively, during which attacks
improved without any stimulation. In these patients, DBS was
not initiated until they reported a return to baseline in terms of
attack frequency. All devices were programmed with a frequency
of 185 Hz and a pulse width of 60 ms.11 Voltages were adjusted
according to self-limiting side effects (diplopia, vertigo,
oscillopsia, and ophthalmoplegia) in single or multiple steps,
depending on the patient. Stimulation parameters were kept
constant for the first 3 months and were adjusted after this if
patients were not responding.
Statistical analysis. IBM SPSS Statistics package v22 was used
for all the statistical analyses.
Percentage change from baseline was used where appropriate.
The data at baseline were assessed for normality using
Kolmogorov-Smirnov test and by inspecting the Q-Q plot and
frequency distribution histogram prior to determining appropri-
ate statistical tests. Whenever the distribution was not normal,
nonparametric tests were used and the median was given instead
of the mean. Wilcoxon signed-rank test was used to compare
treatment effect at each timepoint from baseline. To adjust for
multiple comparisons when present, Bonferroni corrections were
applied by multiplying each test-statistics p value by the number
of comparisons. There were 4 comparisons in the HAL case (for
separate tests between baseline and 3, 6, and 12 months, and last
follow-up), and 2 for QoL and disability scores (for separate tests
between baseline and 6 and 12 months). Statistical significance
was set at 5%. Raw and normalized data were tested and descrip-
tive statistics were reported where applicable.
Research questions. When carried out in patients with refrac-
tory CCH:
1. Does VTA-DBS improve headache frequency, severity, and
headache load? (Class IV evidence)
2. Does VTA-DBS improve disability, mood, and QoL? (Class
IV evidence)
3. Is VTA-DBS safe? (Class IV evidence)
RESULTS Patient sample. Between April 2009 and
November 2013, 21 patients (17 male) with a mean
(SD) age of 52 (10) years underwent VTA-DBS for
CCH. CCH was the sole headache diagnosis in 16
patients (76%). Other primary headaches were
present in the remaining 5 patients (24%),
including episodic migraine, sporadic hemiplegic
migraine, and short-lasting unilateral neuralgiform
headache with conjunctival injection and tearing.
The mean (SD) time from CH onset until surgery
was 15 (7) years. The mean (SD) time from CH
onset until the last follow-up point was 18 (8)
years. Sixteen patients received unilateral DBS
electrode implantation (8 left) for strictly unilateral
cluster CH; the remaining 5 patients (24%)
underwent bilateral DBS electrode implantation for
side-variable CH attacks. Six (29%) patients had
prior ONS implanted with limited or short lasting
effect with a median time of 4 years prior to
undergoing DBS. Of these, 3 patients had the ONS
removed before undergoing DBS surgery (table e-1
on the Neurology® Web site at Neurology.org).
Comorbidities in this patient group included
depression (n 5 10), previous suicide attempts or
ideation (n 5 4), cancer (n 5 3), other chronic
headache syndromes (n 5 5), epilepsy (n 5 3),
Parkinson disease (n 5 1), chronic fatigue syndrome
(n 5 1), stroke (n 5 1), heart disease (n 5 1),
hereditary spastic paraparesis (n 5 1), and
temporomandibular joint dysfunction (n 5 1). Four
patients were smokers and 3 were ex-smokers.
Implanted leads were within a mean (SD) of 0.8
(0.4) mm from the planned target. Postoperatively,
3 patients complained of intermittent diplopia, which
resolved in 2 patients following stimulation parame-
ters adjustment and persisted in the other patient
who had a previous history of ipsilateral trochlear
nerve palsy following a head injury; this diplopia per-
sisted even when stimulation was switched off. One
patient developed a keloid scar over the IPG incision.
A superficial wound infection developed in 1 patient,
which resolved with antibiotics treatment. There was
no surgical mortality or other significant morbidity.
Postoperative follow-up ranged from 4 months to
5 years with 19 patients having at least 1 year of
follow-up.
Frequency and severity of headache attacks (VRS). At the
final follow-up point, there was a 60% overall
improvement in the median headache frequency
from 5 to 2 attacks per day (p 5 0.007). The
percentage of patients who had at least 30% and
50% reduction in median frequency of attacks was
62% and 52%, respectively.
The overall improvement in median headache
severity was 30%, from 10 to 7 points on the VRS
(p 5 0.001). The percentage of patients who had at
least 30% and 50% reduction in median headache
severity on the VRS was 43% and 24%, respectively,
at the final follow-up point (table e-2 shows effect of
DBS on CH attack frequency, severity, and duration
at last follow-up).
Headache load. Eleven patients (52%) showed a max-
imum reduction in the HAL of more than 80% dur-
ing the follow-up period. Within 3 months of
surgery, the median change in HAL was 62%, at 6
months it was 59%, and at 12 months it was 79%
(table 1 and figure 2, A and B).
The percentage of patients who had at least 30%
and 50% reduction in headache load was 81% and
76%, respectively, at the final follow-up point.
Four patients (19%) failed to respond to treat-
ment (,30 reduction in HAL). Three of these had
also failed to respond to ONS treatment previously.
The subset of patients with prior ONS (n 5 6)
had a failure rate of 50% (n 5 3). There was no
change in the median HAL at 3 months, deteriora-
tion of 3% at 6 months, and deterioration of 23% at
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12 months (n 5 6). In this subgroup, the 3 patients
who improved had a modest but meaningful reduc-
tion of the median HAL of 34%, 30%, and 34% at 3,
6, and 12 months, respectively.
Reduction in acute and preventive treatment. Seven
patients were on preventive medications prior to
DBS insertion. Six continued to take preventive
medications after surgery although 4 of these reduced
the dose of a medication and 3 stopped at least
1 medication. One patient increased the dose of
verapamil as it had an improved effect on preventing
attacks post-DBS. Eleven patients were taking
triptans prior to treatment and 12 were using
oxygen. At the last follow-up point, 7 patients were
using triptans and 11 were using oxygen. One
patient started to use triptans again posttreatment as
it was found to be effective whereas previously it
had not. The total monthly triptan intake of the
whole group was 873 doses pretreatment and 376
doses posttreatment, a reduction of 57% (table e-3).
QoL, mood, and disability measures. Median improve-
ment in HIT-6 was 4 points (corrected p5 0.018) at
6 months and 6 points (corrected p 5 0.034) at 12
months. The PCS section of the SF-36 scores showed
an improvement of 13% (corrected p 5 0.038) at 6
months (table 2 and figure 3).
DISCUSSION This open-label prospective study
suggests that MRI-guided and MRI-verified DBS of
the VTA is a safe and effective procedure in
patients with CCH whose symptoms are refractory
to other treatments. Symptomatic improvement was
sustained over time and was accompanied by
significant improvements in a number of QoL scales.
In 1998, a PET study reported increased activa-
tion in the posterior hypothalamic region during
CH attacks, though the maximal activation was cen-
tered over the VTA.26,27 This led to the first DBS
procedure in 2001, with attacks disappearing within
48 hours of starting stimulation.10 This pioneering
group referred to the anatomical target as the poste-
rior hypothalamus rather than the VTA, and went on
to report the first series of 5 patients in 2003 and 19
patients in 2013.11,28 To date, different centers have
published data on over 70 patients with DBS for
medically intractable CCH with varying response rate
but an overall good safety record with the exception
of one fatal intracerebral hemorrhage during a
microelectrode-guided procedure.12–14,28,29
A randomized controlled crossover trial of DBS
for CCH did not show any significant difference
between sham and active stimulation during the
blinded crossover period. However, 1-year outcome
revealed that 6/11 patients had .50% reduction in
Figure 2 Median headache load (HAL) evolution
(A) Median HAL at baseline and over the course of follow-up with amedian absolute deviation
error band. (B) Median HAL of responders and nonresponders.
Table 1 Median headache load
Baseline 3 mo 6 mo 12 mo Last follow-up
Median 696 258 (n 5 17, p 5 0.002) 198 (n 5 16, p 5 0.01) 156 (n 5 20, p 5 0.003) 208 (n 5 21, p 5 0.002)
Median absolute deviation 235 175 155.5 146 162
Median improvement, % 62 59 79 68
Median headache load at baseline and at postoperative follow-up points with percentage of improvement in headache load relative to baseline. The p values
are Bonferroni-corrected; they represent individual tests at each time point relative to baseline (number of comparisons 5 4).
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attack frequency and 3 patients were pain-free. The
difference in outcome may be explained by the short
1-month crossover period within 3 months of surgery.
Such a design does not allow for residual microlesion
effects in the postoperative period or the observed
increase in stimulation efficacy over 3 months of con-
tinuous stimulation in open-label trials.
Our study shows a clear reduction in the head-
ache frequency and severity of CCH attacks with
VTA-DBS, with greater benefit on frequency. How-
ever, using one aspect alone—headache severity or
headache frequency—may not represent the real
response of CCH attacks to an intervention. There-
fore, this study introduces the concept of HAL that
may provide a more meaningful measure of symptom
severity. VTA-DBS resulted in significant improve-
ment in the HAL as early as 3 months postoperatively,
which continued until the final follow-up point.
Table 2 Quality of life, disability, and mood
Baseline 6 mo 12 mo
Median MAD No. Median MAD No. p Value Median MAD No. p Value
MIDAS 137 74 18 100 91 18 0.16 29 29 17 0.08
HIT-6 69 4 19 65 5 19 0.02a 64 8 16 0.03a
HAD-Ab (11) (5) 19 (9) (5) 19 0.22 (9) (5) 17 0.5
HAD-Db (12) (6) 19 (10) (6) 19 0.22 (10) (5) 17 0.32
BDI-II 28 11 18 25 12 18 0.27 20 8 15 0.47
SF-36 PCS 32 6 14 36 9 14 0.04a 35 6 13 0.27
SF-36 MCS 32 9 14 36 12 14 1.10 34 16 15 1.94
Euro-QoL 0.65 0.09 11 0.68 0.07 11 1.25 0.71 0.07 10 0.08
Euro-Scale 49 19 11 55 15 11 0.28 45 17 10 1.89
Abbreviations: BDI-II 5 Beck Depression Inventory II; HAD-A 5 Hospital Anxiety and Depression Scale–anxiety; HAD-D 5 Hospital Anxiety and Depression
Scale–depression; HIT-6 5 Headache Impact Test–6; MAD 5 median absolute deviation; MIDAS 5 Migraine Disability Assessment Score; SF36-MCS 5
Short Form–36 mental summary score; SF36-PCS 5 Short Form–36 physical summary score.
Quality of life, disability, and mood data at baseline and 3, 6, and 12 months postsurgical follow-up. The p values are Bonferroni-corrected; they represent
individual tests at each time point relative to baseline (number of comparisons 5 2).
ap Value # 0.05.
bNormally distributed data presented in mean and SD instead of median and MAD.
Figure 3 Improvement in quality of life, disability, and mood
*p# 0.05. p Values are Bonferroni-corrected; they represent individual tests at each time point relative to baseline (number
of comparisons 5 2 for tests at 6 and 12 months). Median percentage of improvement in quality of life (Short Form–36,
EuroQoL), disability (Migraine Disability Assessment Score [MIDAS], Headache Impact Test–6 [HIT-6]), and mood (Hospital
Anxiety and Depression Scale–anxiety [HAD-A], Hospital Anxiety and Depression Scale–depression [HAD-D]). BDI-II5 Beck
Depression Inventory II; SF36-MCS 5 Short Form–36 mental summary score; SF36-PCS 5 Short Form–36 physical sum-
mary score.
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Nevertheless, the clinical meaningfulness of HAL as a
primary endpoint needs validation by studies in larger
cohorts.
The monthly triptan intake of the group as a
whole dropped by 57% (497 doses per month).
Using current UK costing estimates,30 this can be
calculated to be a saving of £8,291 a month for the
21 patients or around £395 a month per patient on
triptans alone.
None of the QoL, disability, and mood outcome
measures deteriorated following surgery and a num-
ber improved significantly from baseline (HIT-6,
SF-36 PCS, and EuroQol). The largest improvement
was seen in in the SF-36 PCS at 6 months.
Improvement in QoL measures did not have the
same magnitude as that observed with HAL. The rel-
atively long duration of the disease (average 15 years)
may have resulted in socioeconomic and psychosocial
adjustments to chronic illness that are unlikely to
improve immediately following improvement in the
headache symptoms. Other factors to consider are
other comorbidities in our cohort of patients.
The brain region used for DBS was first described
as a surgical target by Sano et al.,31 who performed
stereotactic lesions in 51 patients with pathologically
aggressive behavior. Although this area has been
widely described as the posterior hypothalamus, the
anatomical accuracy of this label has been contested.
The mammillothalamic tract represents the posterior
border of the hypothalamus and the target area lies
posterior to this within the ventral tegmentum of the
midbrain.27,32 This brain region has also been used as
a target in DBS for depression.33
Our general practice is to perform DBS surgery
under general anesthesia when the brain target can
be well visualized with MRI to guide electrode inser-
tion.24,25 However, we elected to perform surgery
under local anesthesia for the first 11 patients. This
allowed intraoperative testing with macrostimulation
to study any possible intraoperative side effects of
stimulation. With higher voltages, these included
tachycardia, raised blood pressure, vertical diplopia,
and a feeling of panic or impending doom. These
effects were reproducible in all tested patients. Once
the procedure was well-established locally, we per-
formed the surgery under general anesthesia, relying
on MRI-verified targeting.
Limitations apply to any open-label study. A pla-
cebo effect cannot be excluded; however, this is
unlikely to be large with follow-up over 1 year. More-
over, there were a number of incidents where attacks
recurred when stimulation was inadvertently
switched off.
The 6 patients who had a short-lasting or no
response to ONS therapy prior to receiving DBS
had a much higher failure rate and no overall
improvement in HAL. Furthermore, those who did
respond to DBS showed a very modest improvement
in HAL when compared to that seen across the entire
patient group. Moreover, 2 of the 5 patients with
bilateral CCH were nonresponders. A failure to
respond to ONS and the presence of bilateral symp-
toms may be predictors of poor outcome following
DBS; however, these patient subgroups are too small
to draw any firm conclusions.
Lack of response to VTA-DBS in some patients
has been reported in previous series in spite of well-
positioned DBS electrodes.32 Despite an increase in
HAL in these patients (figure 2B), our cohort of pa-
tients experienced significant improvement as a
group. Further work into structural and functional
connectivity may reveal underlying differences
between responders and nonresponders, improving
patient selection and outcome of DBS in CH.
This study suggests that MRI-verified VTA-DBS
may be a safe and effective treatment for drug-
refractory CCH and could be considered for suitable
patients who fail conventional treatment. We also
noted positive effects of DBS for CCH on patient-
reported QoL, disability, and mood.
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